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Abstract 
The life sciences sector (and biotechnology in particular) has emerged as a prospective area, and 
attracted a lot of attention recently. Multinational companies in the life sciences seek to explore new 
markets, and, on the other side, governments strive to develop the life sciences sector perceiving it 
as a basis for long-term development. Whilst the R&D activities of global multinationals in life 
sciences still remain concentrated in the Triadic economies, these companies increasingly seek for 
new location to tap the knowledge. New EU member states emerge as such prospective locations. 
Notwithstanding the interest towards this sector, the body of literature on the development of life 
sciences in new EU member states, and particularly, the role of multinational companies, remains 
scant. In this explorative study we attempt to fill this gap and focus on the role of multinational 
companies in the Czech life sciences sector. 
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1 Introduction 
The life science industry is having a significant impact on the health of population and the 
wealth of nations, and has attracted a lot of attention recently. Growth in the life sciences is 
fuelled primarily by the disruptive and creative nature of biotechnology. It is similar to the 
changes provoked by the technological revolution that information and communication 
technologies (ICT) provoked in the recent past. There are profound differences though. 
Because governmental regulations did not play a crucial role for ICT, the major players in 
the sector were start-up firms and small and medium-sized enterprises in general, in the life 
sciences sector the situation is different (Luukkonen and Palmberg, 2007). The sector falls 
under a tight control of national medicine regulatory bodies, characterised by high upfront 
R&D investment and long development times. Thus, in most cases only multinational 
companies possessing enough capital and facilities, and able to comply with regulations can 
operate in the sector; and small companies tailor their strategies to cooperate with them. 
Not only in life sciences, but in most other industries too, multinational companies are 
playing an ever increasing role in global economy, and not only in the production of goods 
and delivery of services, but also in conducting research and development (R&D) on a 
global scale. Already in the mid-1990s, multinationals accounted for a large share in the 
R&D expenditures of the Triad economies (Gassmann and von Zedtwitz, 1999). In 2002, 
measured in terms of R&D expenditures, the 69% of world’s business R&D was 
undertaken by the 700 largest R&D spending firms of the world – of which at least 98% 
were multinational companies (UNCTAD, 2005). Traditionally, multinationals retained 
their R&D functions at the headquarters; unlike other largely internationalised functions. A 
recent trend, however, is the internationalisation of R&D (Granstrand et al., 1993; 
Kuemmerle, 1997; 1999), stimulated by various factors, such as changing technologies and 
shorter product life cycles in the global economy. Multinationals feel the pressure to invest 
more in R&D to succeed on the market. This imperative, coupled with a shortage of skilled 
labour (and its rising cost) in their home bases, lead multinational companies to adopt 
global R&D strategies. 
The superiority of the Triad as a location for R&D is challenged by emerging economies. 
Although the bulk of foreign R&D activities of multinationals are still taking place in 
developed economies, recently R&D expenditures have grown fast in emerging economies 
(UNCTAD, 2005). Therefore the internationalisation of corporate R&D, coupled by 
dynamic growth in non-Triad regions, has changed the global landscape for R&D. 
Countries of Central and Eastern Europe, the new member states of the European Union 
(EU), are emerging as prospective locations for foreign investors too, and not only for 
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manufacturing, but also for higher-value added corporate activities, such as R&D. 
Historically, their science and technology systems were well developed and presently they 
attempt to strengthen their R&D capacities by various measures, including attracting 
foreign investment in R&D. It is estimated that business enterprise R&D in the ten new EU 
members rose from USD 688 million in 1991 to USD 1452 million in 2003 (UNCTAD, 
2005: 287).  
Following these developments, the focus of this chapter is placed on the intersection of the 
sectoral view on the life sciences, with a special interest in foreign direct investment (FDI) 
in R&D. We analyse multinational subsidiaries in the Czech life sciences sector. There is a 
well-established body of literature that deals with the multinationals’ entry mode into a host 
economy, rooted in the pioneering study by Stopford and Wells (1972). Studies on 
subsidiaries are relatively new strand of literature that has burgeoned considerably over the 
recent decennia (Paterson and Brock, 2002), with the subsidiary evolution as a vital 
research issue (Birkinshaw, 1996; Birkinshaw and Hood, 1998). 
While insights from the aforementioned international business theory are helpful for the 
present study, the chapter seeks to contribute to other research area, namely academic 
literature on transformations in the CEE region and EU enlargement. Notwithstanding the 
abundance of literature on the economic transition (Knell, 1992, 1996; Scholtès, 1996, 
Campos and Coricelli, 2002) and the role of FDI in transition (Estrin et al., 1997; Meyer, 
1998), studies investigating knowledge-based activities in CEE economies remain scant 
(Pech and Radosevic, 2006). Developments of life sciences sector (and biotechnology in 
particular) in CEE, the knowledge-based industry of the 21st century, remains largely 
under-researched topic, at best represented by studies on clinical trials (Pal, 1997; Natorff, 
1998; Babic and Kucerova, 2003). Despite seemingly widespread interest in the implication 
of the 2004 EU enlargement, focus of many economic studies is still placed on “old” 
member states, EU-15. Despite some exception (Sansom, 1999; Damborský et al., 2006), 
most studies in life sciences tend to focus on EU-15 (Reiss et al., 2004; Mangematin, 
2004).  
The chapter is an explorative study that seeks to fill this gap in the literature by employing 
qualitative analysis and investigating operations of several multinationals in the life 
sciences in the Czech Republic, one of the regional leaders. Focusing on only one country 
allows us to have a deeper and more detailed look, yet since many features of the Czech life 
sciences sector are common to other countries in the CEE region, the research is relevant 
for them too.  
The chapter is structured as follows. Section 2 sets the stage by providing insights into the 
life sciences sector. Section 3 presents a qualitative analysis of strategies and operations of 
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subsidiaries in the life sciences sector of the Czech Republic. Section 4 concludes and 
provides policy implications. 
2 Life Sciences 
Life sciences are a global innovative industry, widely regarded as one of the most 
promising frontier technologies for the coming decades. It has recently attracted increasing 
attention as an important tool that has transformed the route for new drug discoveries and 
deliveries and can in general improve the quality of life. Life sciences may be broadly 
defined as including the scientific discipline of life and of living organisms. The term is 
used as a collective name for the pharmaceutical and biotechnology industries as well as 
medical technologies, clustered together due to their interdependence and fuzzy borders 
between them. The interdependence between pharmaceuticals and biotechnology emerged 
in the second half of the 1970s when several pharmaceutical multinationals started 
partnering with biotechnological start-ups to gain knowledge (Roijakkers and Hagedoorn, 
2006). Most biotechnology companies are small, they account for the bulk of innovative 
activity and the business model is based on commercialisation of university research that 
may lead to major scientific and technological changes; in most cases, this 
commercialisation depends mainly on the efforts of large (multinational) companies 
(Kenney, 1986; Powell, 1996; McKelvey, 1996). By now collaboration in R&D between 
pharmaceutical multinationals and biotechnology companies has increased dramatically 
(Roijakkers and Hagedoorn, 2006). Moreover, pharmaceutical multinationals not only 
engage in partnering with biotechnology start-ups, but they also acquire them, as a way to 
withstand competitive pressure from generic drugs companies.  
Different typologies have been designed to study the R&D-intensity of industries (for 
example, UNCTAD, 2005: 108). According to the UK Department of Trade and Industry, 
pharmaceuticals and health is the first and the most R&D-intensive group out of five groups 
(DTI, 2006). It consists of pharmaceuticals & biotechnology (R&D-intensity: 14.9%) and 
health care equipment & services (R&D-intensity: 6.4%), where R&D-intensity is defined 
as direct R&D expenditures as a percentage of production (gross output). Moreover, the 
global sector is characterised the growth of R&D expenditures which is induced by a 
number of factors, such as ageing of population in developed countries and market growth 
in developing ones. As for the biotechnology, it is a relatively young industry, but it has 
shown an impressive and effective development over the past years, pushing the boundaries 
of conventional medicine into the fields of genomics, molecular biology, bio-medicine, bio-
informatics, etc. 
The high level of R&D-intensity of the life sciences sector implies that linkages between 
corporate R&D activities (including research and clinical trial) and host-country 
  
 
8
science/research systems are very important. In other words, strong links between public 
sector and industry are crucial for commercialisation of products (Meyer-Krahmer and 
Reger, 1999).  
The life sciences sector is heavily concentrated in the leading spots of the Triad, with the 
US taking the lead and surpassing Europe in the amount of R&D investment and 
production. The global life sciences sector is set to grow, which in turn forces 
multinationals to search for new cost-effective locations to remain competitive. Owing to 
the increasing demand for innovative drugs and an increasing patient base, CEE economies 
have a good potential. The geographical proximity to advanced Western European markets 
is a key advantage. Moreover, the CEE economies have a reasonable environment for 
knowledge-based activities of multinational companies and development of life sciences 
industry in particular, owing to a relatively strong scientific and technological base and a 
critical mass of skilled human resources. 
The 2004 accession to the EU is a major factor in the development of the sector. Joining the 
European common market implies that a product developed and manufactured in any 
member state can be sold across the Union. Apart from the classic benefits of regional 
economic integration for multinationals in terms of enlarged market, the Union is set to 
play a decisive role in promoting knowledge-based economy and in the life sciences 
specifically. For example, in January 2002, the European Commission adopted a Strategy 
for Europe on Life Sciences and Biotechnology”, which proposes a comprehensive 
roadmap of policy orientations and an action plan up to 2010. 
Many governments in the region have realised the potential of the sector and design and 
implement respective public policies (BioPolis Report, 2007). In the process of transition 
the sector was largely neglected; and only recently governments in region declared the 
sector a priority. The biggest challenge inherited from the past is a separation between 
academic research and industry; not all CEE countries have made progress in this area 
(BioPolis Report, 2007). 
The pharmaceutical market in the CEE countries is relatively small in comparison to the 
Western Europe or the US. In 2006 it was estimated at USD 9.2 billion, and it is expected 
to reach around USD 14 billion by 2010, still being around 5% of global pharmaceuticals 
(Miriyam, 2007). Although domestic pharmaceutical and biotechnology companies are 
active in the life sciences sector in CEE countries, it is characterised by the strong presence 
of subsidiaries of multinational companies, which have been a driving force behind the 
growth in the sector. 
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Academic literature has extensively investigated drivers of FDI and has distinguished its 
four main motives (Dunning, 1993). Three of them (market-seeking, efficiency-seeking, 
strategic asset-seeking) help explain investment behaviour of multinationals in the CEE life 
sciences sector. 
Market-seeking FDI implies that a multinational company establishes its subsidiary to serve 
a host-country market. In the CEE region, market-seeking FDI is motivated by rapid 
economic growth and a largely under-served population. Increased demand from both 
public and private healthcare is to lead to growth in sales of both branded and generic 
drugs, although generics dominate over the brands due to a lower purchasing power than in 
the West. Moreover, since the CEE economies became part of the regional bloc, the EU, 
non-EU investors are attracted by the magnitude of the Single European market. 
Efficiency-seeking FDI is carried out with the purposes of restructuring existing production 
through rationalisation and locating some parts of the value chain in places which provide 
lower costs. In the CEE countries, efficiency-seeking FDI is attracted by the low cost of 
manufacturing, and primarily, low cost of labour. Additionally, the search for cost-effective 
locations is driven by the increasing R&D costs that pharmaceutical and biotechnology 
multinationals have to bear.  
This search for cost-effective destinations for R&D corresponds to the type of the asset-
seeking FDI, investments in strategic assets (human capital, technology, etc). The CEE 
countries have a strong technological legacy; multinationals are attracted by the presence of 
universities and research institutes involved in life sciences. Although, performance of the 
CEE countries in terms of attracting FDI in path-breaking research is very moderate, since 
mid-1990s they have emerging as advantageous locations for clinical trial. The decisive 
factors have been availability of homogenous, drug-naive patient base, the high treatment 
compliance rates of patients and high ratio of doctors per capita of population. As the 
clinical trials must comply with the EU regulations, more multinational pharmaceutical 
companies are focussing on the new EU member states, which offer excellent location for 
such clinical development activities (Pal, 1997; Natorff, 1998; Babic and Kucerova, 2003). 
The quantity of research conducted in these countries is increasing. The three largest new 
EU member states – Czech Republic, Hungary and Poland – host up to 1000 studies 
annually. New EU member states have lower clinical development costs and less regulation 
as opposed to traditional locations in Western Europe. The governments of new EU 
member states have incorporated the European legislation into national law before the 
accession to the Union, including Directive 65/65/EEC, the first and fundamental 
pharmaceutical framework directive in the EU, and Directive 2001/20/EC on the clinical 
trials. 
  
 
10
Undoubtedly, the CEE region is not a homogenous block. BioPolis Report (2007) groups 
new EU member states in three clusters based on the degree of advances in the life 
sciences. Cluster 1 includes the countries closing the gap with the EU-27 (Czech Republic, 
Estonia, Hungary and Slovenia). Cluster 2 consists of countries making progress (Poland 
and Slovakia) and finally, Cluster 3 unites weak performers (Bulgaria, Latvia, Lithuania 
and Romania). 
Czech Republic, belonging to Cluster 1, emerged as a dynamic economy. During the 
transformation period, the country has greatly benefited from a large amount of FDI, having 
recorded one of the highest FDI stock per capita in the region. The FDI flow has been 
stimulated by the introduction of a transparent system of investment incentives in 1998. 
CzechInvest, the Czech national investment agency, has identified nine key investment 
areas, including life sciences and medical devices and R&D. Within R&D, six priority 
areas are defined, including molecular biology, biomedicine and biotechnologies, as well as 
development of new materials meant to advance life sciences. Pharmaceutical companies 
investing in production in the Czech Republic are eligible for corporate tax relief for up to 
ten years, job creation grants, training and retraining grants and site support. Subsidies to 
business activity and training and retraining are available for technology centres and 
applied R&D. 
Essentially, three main groups of players can be identified in the Czech life sciences sector. 
These are research institutes and universities, domestic companies and subsidiaries of 
foreign multinational companies. According to the Czech Biotech Report (2007), at the 
beginning of 2007 there were 57 biotechnology companies and 308 biotechnology research 
entities in the country. A substantial number of the Czech biotech companies cooperate 
closely with big pharmaceutical players in the Czech market, operating as either a supplier 
base for pharmaceutical substances or conducting subsequent research and contractual 
work. US and European pharmaceutical multinational companies dominates the sector and 
their production is exported to other European markets and to the rest of the world. 
In such a knowledge-intensive sector as life sciences, research institutes play a crucial role. 
The Czech Republic possesses a network of research institutes spread across the country. It 
is no coincidence that biotechnology clusters have emerged in the university cities. Brno, 
the second largest city in the Czech Republic, is becoming a hub of biotech companies. 
Gate2Biotech project developed by The South Moravian Innovation Centre, in partnership 
with CzechInvest, is a specialised biotechnology web-site which is to be the reference point 
for all the activities in the biotechnology sector. 
Most of research institutes in the area of life sciences belong either to universities, to the 
Ministry of Health or the Academy of Sciences of the Czech Republic. The Academy of 
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Sciences is the national centre of non-university basic and applied research. It unites 53 
institutes engaging in research in the natural, technical and social sciences and the 
humanities. There are three biomedical institutes of the Czech Academy of Sciences – 
Institute of Experimental Medicine, Institute of Physiology and Institute of Microbiology. 
University professors and PhD researchers become increasingly involved in common 
research projects with industry. For instance, the University of Veterinary and 
Pharmaceutical Sciences in Brno is engaged in partnerships with companies, such as 
Zentiva and Spofa. 
The International Clinical Research Centre is planned to become an important player in the 
sectoral innovation system of the Czech life sciences. This clinical-research-educational 
centre established in 2006 in Brno is a result of collaboration between Czech scientists and 
the Mayo Clinic, a US non-profit university hospital. The International Clinical Research 
Centre can be a platform for strengthening Euro-US collaboration in medical research and 
education. The project is valued at USD 100 million and around 250 researchers are 
employed. The technology parks provide infrastructure suitable for growth within the 
industry  
Several institutions perform clinical testing of drugs. The State Institute for Drug Control in 
Prague is the highest authority supervising clinical trials. The company I.Q.A. founded as a 
spin-off from the Research Institute of Pharmacy and Biochemistry is engaged in 
preclinical and clinical testing of drugs. Other companies doing all phases of clinical trial 
are Zak-Pharma services (Brno), Cepha (Prague), Clinst (Prague), Pharm Test (Hradec 
Králové). 
 
3. Multinational Companies in the Czech Life Sciences 
Major US and European multinational companies are important players in the Czech 
economy and in the life sciences sector in particular. According to the OcoMonitor 
database, from 2003 till August 2007 alone, the Czech Republic recorded a total of 4 new 
investment projects in this sector, representing 17% of the CEE total (of 23 cases), 
compared to 9% for Poland, 17% for Russia and 22% for Hungary. The list of investors 
present in the Czech Republic include such names as Lonza (Switzerland), Arrow 
International (US), Amgen (US), Eisai (Japan), Molnlycke Health Care (Sweden), Covance 
(US), Olympus (Japan), Paul Hartmann (Germany), Synthon (The Netherlands), Johnson & 
Johnson (US). Moreover, many medical producers are present, inter alia, B Braun Medical 
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(Germany), Carl Zeiss (Germany), Axel Johnson International (Sweden), Philips Medical 
Systems (The Netherlands), Thermo LabSystems Corporation (USA). 
In this section we look at several examples of multinationals entering the Czech life 
sciences sector, and draw conclusions on the basis of these observations. We proceed with 
the analysis taking an entry mode as a departure point. Essentially, there are two main 
modes of entry – greenfield investment and mergers and acquisitions. Greenfield FDI 
denotes investment projects entailing establishment of new production facilities. Whereas 
many multinational companies prefer greenfield investment, it is acquisitions that became 
the key mode of global FDI since the late 1980s, and they currently shape the global pattern 
of FDI activities (UNCTAD, 2000, 2006). The popularity is explained by the fact that it 
enables quick entry and facilitates access to local resources and networks. For the host 
country, the main difference between these two modes lies in the immediate of short-term 
effects (such as capital formation and employment generation) since in the long run the 
impact on the host country can be difficult to distinguish (UNCTAD, 2000, 2006). 
The cases of acquisition were widespread during the transition period as foreign 
multinational companies acquired state-owned companies in a process of privatisation. 
Still, it is popular nowadays. Immunotech, a Czech company focused on R&D and the 
production of diagnostic kits for medical use, was acquired by the US company Beckman-
Coulter, a leading producer of biomedical testing instrument systems. Immunotech itself 
was a subsidiary of the French company, and it was established on the basis of the 
Radioisotope Research and Application Institute in Prague.  
Galena, one of the leading Czech pharmaceutical companies with 120-old history based in 
the city of Opava, was acquired in 1994 by the IVAX Corporation, headquartered in Miami, 
through a privatisation deal. The Czech Brno-based company Lachema began to focus on 
drugs at the end of the 1960s. In 1999 the Croatian multinational pharmaceutical company 
PLIVA acquired the majority of the shares of the company. At the end of 1999, PLIVA-
Lachema was purchased by the US corporation Barr Pharmaceuticals. 
Although the privatisation process ended mostly by the 2000s, an acquisition still remained 
a popular mode of entry. In 2002, Baxter Corporation, the global provider of medical 
products and services bought a site and unfinished building from SEVAC, a state-owned 
enterprise, initially established as the Institute of Sera and Vaccines. Since then, Baxter has 
invested around almost USD 56 million to develop the subsidiary, which now has around 
200 employees. In 2003 the Dutch company Zentiva acquired two drug producers – 
Slovakofarma in Slovakia and the Czech Léčiva. Zentiva’s main shareholder is another 
multinational, France’s Sanofi-Aventis. 
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Acquisition of manufacturing units has been an important mode of entry into a host 
economy for multinationals. In many cases an acquired enterprise contains technological 
capabilities, which can either be utilised by integrating into the new corporate network or 
downsized. The Czech company Galena acquired by IVAX retained it R&D department 
dedicated to biotechnology and remained embedded in the Czech national innovation 
system. It cooperates with national universities and research institutes in the development 
of active pharmaceutical ingredients.  
Acquisition of stand-alone R&D units, such as research institutes in a host economy is a 
very specific case. In the centrally planned economic system, the organisational structure 
for research, development and innovation was highly fragmented. There was a traditional 
separation between a network of branch R&D, project design and product design 
organisation on one side, and a network of enterprises on the other (Hanson and Pavitt, 
1987). This fragmentation was an obstacle for innovation, but could be managed by the 
central planning agencies. With the demise of the command economy, this traditional 
fragmentation led to unpredictable developments. Demand for R&D from manufacturing 
enterprises significantly decreased and many research institutes found themselves on the 
verge of bankruptcy. In the light of these developments, the decision made by the Czech 
government in the 1990s to privatise some research institutes is not surprising. It meant that 
state-owned research institutes were available for acquisition (not only for domestic, but for 
foreign investors, too). Acquisition of state-owned research institutes represents a typical 
case of asset-seeking FDI, attracted by strategic assets created by a host economy. 
Multinational companies enter a host economy by acquiring R&D facilities, without prior 
experience in a host country and prior investment in less advanced corporate functions. The 
case of Lonza Group is illustrative in this respect. The Swiss chemical and biotechnology 
company, headquartered in Basel, is one of the world’s leading suppliers to the 
pharmaceutical, healthcare and life science industries. As early as in 1991, the company 
began co-operation with Research Institute for Biofactors and Veterinary Drugs, and in 
1992 it was acquired. A noteworthy observation is that the company entered the Czech 
market through acquisition of the most advanced corporate function (R&D). Later it 
progressed to more downstream functions, as a newly-established Lonza Biotec, a Czech 
subsidiary of the Group, started production of L-Carnitin. In 2002 Lonza began 
considerably expanding its facilities. Company’s operations were expanded in 2004 (adding 
more downstream processing capacities). In 2005, the company decided to strengthen its 
R&D capabilities, and in 2006 a new R&D centre, worth of USD 18 million and employing 
50 people, was opened in Kouřim. 
It could have been assumed that potential for asset-seeking FDI in the Czech life sciences 
sector has been fully exhausted after privatisation / acquisition of state-owned research 
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institutes in the 1990s. Nowadays, it is private national R&D firms that remain the target 
for acquisition. For examples, in August 2007, the US-based international clinical trial 
company Medpace Inc. announced acquisition of the 500-employee Czech contract 
research organisation Monax. It is indicative that with this deal, Medpace aims to 
strengthen its presence in Europe, in addition to its existing offices in Belgium, Germany 
and the Netherlands. 
In case of greenfield investment, a host country should be able to outcompete alternative 
locations short-listed by a multinational company in terms of package of investment 
incentives, provision of infrastructure and facilitation of entry. Laminar Medica is 
illustrative in this respect. The company headquartered in Tring (UK) specialises in design, 
test, manufacture and validation of transport systems for healthcare facilities. It has a 
warehouse facility in Germany and a manufacturing plant in the Czech Republic. The plant 
that became operational in 2005 as a result of a greenfield investment project. In 2003 the 
company started looking for a new location in Eastern Europe to match the demand of an 
expanding consumer base, while taking into account lower costs of prospective locations. It 
considered the Czech Republic, Poland and, to a lesser extent, Hungary and Austria, but 
finally chose the Czech Republic thanks to the favourable conditions in the Czech Republic 
and offered investment incentives. 
In 2006 Covance Inc. (US) announced the opening of a clinical development office in 
Prague. This new office supports Covance’s clinical trial operations in the Czech Republic 
and Slovakia. It would complement the network of existing clinical development offices, 
inter alia, in Warsaw and Budapest. The investment amounted to USD 21.9 million and 58 
new jobs were created. 
It is worth noting that many foreign multinational companies established partnerships with 
domestic firms or research institutes before entering the Czech economy through an 
acquisition or a greenfield investment. An example of a joint-venture with a domestic 
company leading to a greenfield investment is a pharmaceutical company Ferring. In 1993, 
this Swiss multinational entered in a joint-venture with Léčiva, the largest pharmaceutical 
company in the Czech Republic at that time. The company started greenfield construction 
in 1997, and in 1999 Ferring Léčiva became fully owned by Ferring. 
The entry of the biopharmaceutical company Gilead Sciences in the Czech Republic is a 
result of partnership with a research institute. In 1991, the multinational company, 
headquartered in California and operating in North America, Europe and Australia, entered 
into license agreement with The Institute of Organic Chemistry and Biochemistry (IOCB) 
of the Czech Academy of Sciences. In 1992, development of small molecule antiviral 
therapeutics was ushered in with the licensing of nucleotide compounds discovered in 
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IOCB and a research institute in Belgium. In July 2006 Gilead Sciences announced a 
donation to IOCB in order to establish a Gilead Sciences Research Centre. Gilead pledged 
to provide USD 1.1 million annually to IOCB for an initial five-year period in order to fund 
the Centre’s operations and ongoing research activities. The Centre will consist of selected 
research groups led by scientists from IOCB. Another agreement signed between these two 
parties stipulates that Gilead would provide patent services to IOCB. 
These several examples of global multinational companies entering the Czech life sciences 
sector with different motivations and strategies provide rich food for thought. First of all, 
we consider establishment of a subsidiary without any R&D capacities. It would correspond 
to market- or efficiency-seeking FDI. A multinational company can decide to establish a 
manufacturing unit through a greenfield investment. This is a traditional approach under 
which a multinational company establishes a subsidiary producing goods and products 
already manufactured in the corporate network elsewhere. In the case of pharmaceuticals, 
the costs of setting up a new production line are higher since a company should have the 
necessary certification of the manufacturing processes. In case of acquisition, a 
multinational would buy a firm possessing manufacturing capacities and gain immediate 
access to the market. Both modes of entry can be beneficial for the host economy since the 
acquisition of existing firms integrates these manufacturing facilities into the global 
corporate network, and in the case of a greenfield investment the country receives capital 
inflows and new jobs are created. 
Another case is a subsidiary combining manufacturing and R&D capacities. This type of 
investment may unite market-, efficiency, and/or resource-seeking FDI. In the case of a 
greenfield investment, it is the most desirable type of FDI for the host country since the 
economy benefits from capital inflows, job creation and strengthening of the knowledge 
base. In the case of an acquisition, a domestic firm becomes part of the global corporate 
network. While the production capacities are usually retained, it is questionable whether the 
R&D facilities will be preserved and integrated into the global network. 
A somewhat less frequent case is the entry to the host economy in the form of stand-alone 
R&D, which results from the trend of corporate R&D internationalisation. It is typically an 
asset-seeking FDI. Investment promotion agencies of many countries specifically target and 
compete for a tiny share of the best FDI, i.e. FDI in R&D. However, attraction of R&D-
related FDI is not an end in itself, integration of these subsidiaries into the host national 
innovation system is a key task.  
A very specific case is an acquisition of stand-alone R&D facility. As it was noted, in the 
Czech Republic it was exemplified by acquisition of state-owned research institutes by 
multinational companies in the process of privatisation in the 1990s. The proponents of this 
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approach believed in the superiority of market forces; it was suggested that privatisation of 
the science and technology sector would solve the problems inherent in the socialist 
economy. The claim was that although the state was losing control over these R&D 
capabilities, they became effectively integrated into the global economy, and the issue of 
ownership was not relevant as long as they are physically present in the national economy. 
On the other hand, the opponents were concerned about the loss of national control over 
R&D capabilities as the biggest disadvantage of the acquisition of research institutes by 
multinationals. Since the control is transferred to the headquarters of a multinational 
company, the state remains powerless, and a multinational company can downsize or even 
close down these R&D labs. 
 
4. Conclusions and Policy Implications 
The biotechnology and life sciences sector emerged as a prospective area, and it can be 
labelled as “the 21st century gold rush”. On one hand, traditional pharmaceutical 
multinationals explore new opportunities in the biotechnology and seek to reinforce their 
positions on the market. On the other hand, governments try to jump on the bandwagon and 
try to develop the national life sciences industry as they are afraid to be left out of what is 
perceived as a source for high-end economic development. 
Since the life sciences sector (and pharmaceuticals in particular) is highly globalised, 
targeting of FDI in the life sciences has become a natural way to develop this industry. This 
FDI promotion typically includes granting investment incentives such as grants, tax rebates 
and tax holidays. 
However, unlike the gold rush in California, which was driven by resource-seeking 
motives, the biotech gold rush is driven by asset-seeking motives, meaning that life 
sciences multinationals invest in locations that offer a pool of educated workforce, unique 
knowledge and expertise. Several CEE countries, new EU member states, and Czech 
Republic in particular, emerge as such locations.  
The Czech Republic offers investment incentives for FDI projects in the life sciences too, 
but the real motivation to enter the market is based on a different rationale, namely the 
access to assets. The country had a strong science foundation in pharmaceuticals and 
natural sciences in the past. Successful privatisation of the pharmaceuticals industry 
provided a boost in the development of the life sciences sector in the country. Hence, it is 
not surprising that acquisition of state-owned enterprises was the most common way for 
multinationals to enter the Czech life sciences industry. Moreover, acquisition of state-
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owned research institutes is an interesting case per se. Presently, as the mass privatisation 
ended, multinational acquire private R&D companies. However, R&D activities are still 
limited to clinical trials and do not encompass ground-breaking research. 
The developments in the Czech life sciences sector should be regarded through the 
country’s membership in the EU, as the country belongs to the 27-member block that 
fosters common market and enforces harmonious regulatory environment. Some 
reservation about EU membership should be expressed however; this competitive 
advantage is being eroded as more countries join the bloc. In this way, the current study, 
although focusing on only one country is relevant for several other new EU member states. 
Previous studies (Thomas, 1994) on the public policies to promote pharmaceutical sector 
show that that policy shaping the local network and stimulating demanding competitive 
environment is much more effective than that protecting the local market and 
desynchronising it from the global market. There seems to be that most CEE countries and 
Czech Republic in particular chose the first way. Such competitive creative environment 
would make domestic firms stronger, attract newcomers and will stimulate evolution of 
subsidiaries. In fact, FDI policy should extend from initial attraction of FDI to supporting 
the already existing subsidiaries to evolve towards a broader scope of activities and develop 
R&D capacities (Costa and Filippov, 2007). CzechInvest is set to provide “after-care” 
support to foreign investors. 
Albeit this process is largely determined by corporate strategy on the level of headquarters, 
the subsidiary management can play a role, especially if it sees the opportunities on the 
market, not only in terms of increase of sales but also access to knowledge. As the analysis 
showed, sourcing of knowledge by multinational companies is taking place not only 
through formal acquisition of domestic firms or research institutes, but more importantly, 
through co-operation, partnership, strategic alliances with domestic companies. This co-
operation should be further promoted for the benefits of both sides. Moreover, policies 
should stimulate universities and research institutes to understand market issues and engage 
in demand-driven research. 
The present explorative study was an attempt to contribute to the scant literature on the 
formation of the life sciences sector in the new EU member states catching up with EU-15 
(exemplified by the Czech Republic), and the role of multinationals in this process. It can 
be concluded that this area represent a promising research avenue and further research is 
needed. 
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